文献速递免疫规划传染病防控与疫情报告

市售疫苗对抗犬钩端螺旋体病的效力:系统综述与Meta分析

Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2022-02-10

本研究通过系统综述与Meta分析评估市售钩端螺旋体疫苗对犬的效力,纳入13项攻毒试验和8项观察性研究,涵盖12个疫苗品牌。汇总结果显示,接种疫苗的犬发生临床疾病和肾脏带菌状态的相对风险分别为0.16和0.12,总体保护率分别为84%和88%,但部分血清型保护不一致,免疫力在实验条件下至少持续一年。

要点

  • 接种疫苗犬临床疾病相对风险0.16,肾脏带菌状态相对风险0.12,均低于未接种对照。
  • 总体保护率:临床疾病84%,肾脏带菌状态88%。
  • Canicola、Australis和Grippotyphosa血清型的保护不一致,部分疫苗品牌存在差异。

核心结论

  • 市售钩端螺旋体疫苗可提供总体84%的临床疾病保护和88%的肾脏带菌状态保护。
  • Canicola、Australis和Grippotyphosa血清型的保护不一致,主要归因于诱导实验感染的方法学困难。
  • 实验条件下疫苗诱导的免疫力至少持续一年,但MAT滴度持续时间与保护不相关。

研究设计与样本

  • 系统综述与Meta分析,检索5个电子数据库,方案在PROSPERO注册(CRD42020178194)。
  • 纳入13项攻毒试验和8项观察性研究,涵盖12个疫苗品牌。
  • 主要结局为预防临床疾病和肾脏带菌状态的能力及免疫持续时间,使用SYRCLE工具评估偏倚风险。

主要发现

  • 接种疫苗犬发生临床疾病的相对风险为0.16,发生肾脏带菌状态的相对风险为0.12,均低于未接种对照。
  • 研究间异质性低,但各项研究用于定义结局的方法学和参数不同。
  • 市售疫苗总体提供84%的临床疾病保护和88%的肾脏带菌状态保护。
  • Canicola、Australis和Grippotyphosa血清型的保护不一致,部分疫苗品牌存在差异。
  • 实验条件下免疫力至少持续一年,但MAT滴度持续时间与保护不相关。

关键数值与推荐

  • 临床疾病相对风险0.16,肾脏带菌状态相对风险0.12(接种疫苗犬 vs 未接种对照)。
  • 总体保护率:临床疾病84%,肾脏带菌状态88%。
  • 研究间异质性低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究间用于定义结局的方法学和参数不同。
  • Canicola、Australis和Grippotyphosa血清型的保护不一致,主要归因于诱导实验感染的方法学困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leptospirosis is a worldwide distributed zoonosis that affects most mammal species, including dogs and humans. Vaccination is the main strategy to control disease and urinary shedding of leptospires in dogs; however, there are few studies in the literature reporting the efficacy of commercially available vaccines. OBJECTIVES: To access and compare the efficacy of commercially available leptospiral vaccines dogs using a quali-quantitative systematic review. METHODS: The main outcome of interest was the ability to protect dogs against clinical disease and renal carrier state, as well as promoting duration of immunity. Experimental and observational study designs were eligible for inclusion, and methodology was validated by PROSPERO, under registration CRD42020178194. Five electronic databases were searched. Data about population, methodology and outcomes were extracted in a dichotomous or continuous manner. Evaluation of risk of bias for individual studies was assessed using SYRCLE tool. RESULTS: Thirteen challenge trials and eight observational studies were included, comprising 12 vaccine brands. In the calculated pooled effect, vaccinated dogs had a reduced Relative Risk of developing clinical disease (0.16) and renal carrier state (0.12) when compared to unvaccinated controls. The heterogeneity between studies was low; however, methodologies and different parameters were used in the studies to define the outcomes. CONCLUSIONS AND CLINICAL IMPORTANCE: Our study has demonstrated that commercially available vaccines against leptospirosis can provide an overall 84% protection against clinical disease and 88% against renal carrier status. Protection against clinical disease and carrier status by serovars Canicola, Australis and Grippotyphosa is inconsistent for some vaccine brands, and such hurdle is mostly attributed to methodological difficulties in inducing experimental infection using these serovars. Evidence shows that immunity provided by the vaccines included in our meta-analysis can persist for at least one year under experimental conditions. However, the duration of MAT titers induced by vaccination do not correlate with protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bergmann Esteves S, Moreira Santos C, Ferreira Salgado F, et al. Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis. Vaccine. 2022. PMID: 35153090. doi:10.1016/j.vaccine.2022.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。